David A. Putnam

Dr. David A. Putnam

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Nature Materials
Verified
Journal Article
Closed access
PDF file
David A. PutnamDavid A. Putnam
David A. Putnam

1 August 2007 in Progress in Polymer Science
Verified
Journal Article
Closed access
SWSharon Y. Wong
Sharon Y. Wong
JPJeisa M. Pelet
Jeisa M. Pelet
David A. PutnamDavid A. Putnam
David A. Putnam

27 July 2001 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DLDavid M. Lynn
David M. Lynn
DADaniel G. Anderson
Daniel G. Anderson
David A. PutnamDavid A. Putnam
David A. Putnam
RLRobert Langer
Robert Langer

15 July 2006 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
AGAmy C. Richards Grayson
Amy C. Richards Grayson
ADAnne M. Doody
Anne M. Doody
David A. PutnamDavid A. Putnam
David A. Putnam

27 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DCDavid J. Chen
David J. Chen
NONikolaus Osterrieder
Nikolaus Osterrieder
SMStephan M. Metzger
Stephan M. Metzger
EBElizabeth Buckles
Elizabeth Buckles
ADAnne M. Doody
Anne M. Doody
David A. PutnamDavid A. Putnam
David A. Putnam
As new disease threats arise and existing pathogens grow resistant to conventional interventions, attention increasingly focuses on the development of vaccines to induce protective immune responses. Given their admirable safety records, protein subunit vaccines are attractive for widespread immunization, but their disadvantages include poor immunogenicity and expensive manufacture. We show here that engineered Escherichia coli outer membrane vesicles (OMVs) are an easily purified vaccine-delivery system capable of greatly enhancing the immunogenicity of a low-immunogenicity protein antigen without added adjuvants. Using green-fluorescent protein (GFP) as the model subunit antigen, genetic fusion of GFP with the bacterial hemolysin ClyA resulted in a chimeric protein that elicited strong anti-GFP antibody titers in immunized mice, whereas immunization with GFP alone did not elicit such titers. Harnessing the specific secretion of ClyA to OMVs, the ClyA-GFP fusion was found localized in OMVs, resulting in engineered recombinant OMVs. The anti-GFP humoral response in mice immunized with the engineered OMV formulations was indistinguishable from the response to the purified ClyA-GFP fusion protein alone and equal to purified proteins absorbed to aluminum hydroxide, a standard adjuvant. In a major improvement over current practice, engineered OMVs containing ClyA-GFP were easily isolated by ultracentrifugation, effectively eliminating the need for laborious antigen purification from cell-culture expression systems. With the diverse collection of heterologous proteins that can be functionally localized with OMVs when fused with ClyA, this work signals the possibility of OMVs as a robust and tunable technology platform for a new generation of prophylactic and therapeutic vaccines.

1 July 2001 in Journal of Controlled Release
Verified
Journal Article
Closed access
CPC Perez
C Perez
ASA Sanchez
A Sanchez
David A. PutnamDavid A. Putnam
David A. Putnam
DTD Ting
D Ting
RLR Langer
R Langer
MAMaria Jose Alonso
Maria Jose Alonso